Abstract 4487: Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer
Anniina Färkkilä(University of Helsinki), Panagiotis A. Konstantinopoulos(Dana-Farber Cancer Institute), Steven Waggoner(University of Chicago), Alan D. D’Andrea(Dana-Farber Cancer Institute), Gini F. Fleming(University of Chicago Medical Center), Jia‐Ren Lin(Harvard University), Ursula A. Matulonis(Dana-Farber Cancer Institute), Yinghui Zhou(Tesaro (United States)), Peter K. Sorger(Harvard University Press), Pamela N. Münster(University of California, San Francisco), Elizabeth M. Swisher(University of Washington), Huy Nguyen(Brigham and Women's Hospital), Julie R. Graham(Tesaro (United States)), Sandro Santagata(Harvard University), Bruce J. Dezube(Xilio Therapeutics (United States)), Julia Casado(University of Helsinki)
Cited by 0
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Copper induces cell death by targeting lipoylated TCA cycle proteins
|Science|2022|4.6k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k